Ovid Therapeutics Inc.
OVID· Nasdaq
Released Mar 8, 2024, before the open
10-K filed Mar 8, 2024, 68 days after period end · 0001628280-24-009809
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $142.00K | $46.28K | $0.00 | — |
| Net Income | -$15.32M |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| -$11.50M |
| -$26.00M |
| -$22.03M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.